Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2015 48 168 M
EBIT 2015 17 119 M
Net income 2015 11 403 M
Debt 2015 10 107 M
Yield 2015 3,14%
Sales 2016 50 294 M
EBIT 2016 18 299 M
Net income 2016 12 519 M
Debt 2016 5 841 M
Yield 2016 3,35%
PER 2015 19,54
PER 2016 17,83
EV / Sales 2015 4,94x
EV / Sales 2016 4,64x
Capitalization 227 620 M
More Financials
Company
Roche Holding AG operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics.It operates business through two divisons: Pharmaceuticals and Diagnostics.The Pharmaceuticals divison comprises the two business segments Roche Pharmaceuticals and Chugai,... 
Sector
Pharmaceuticals
Calendar
07/23Earnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07/06 Drug companies still supplying Greece after 'No' vote
07/03 Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount
06/30 U.S. seeks up to $3.35 billion in Novartis kickback lawsuit
06/30DJROCHE : Announces Positive Results From Studies on Multiple Sclerosis Drug
06/30 ROCHE : Genentech :’s ocrelizumab Significantly Reduced Both Relapses and ..
06/29 Drugmakers warn Greek medicine supply 'may be in jeopardy'
06/19DJNOVARTIS CEO : Roche Stake Would No Longer Have to Be Sold at Premium
06/16 Energy and medicine top import risk list as Greece teeters
More news
Sector news : Pharmaceuticals - NEC
05:43pDJNovartis Heart Failure Drug Approved by FDA
05:37pDJNovartis's Heart Failure Drug Is Approved by FDA - Update
05:13pDJNovartis's Heart Failure Drug Is Approved by FDA - Update
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions